Sevabertinib (Hyrnuo) for NSCLC
Abstract
Sevabertinib (Hyrnuo – Bayer), an oral kinase inhibitor, has received accelerated approval from the FDA for treatment of adults with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) with human epidermal growth factor 2 (HER2) tyrosine kinase domain activating mutations who had received prior systemic therapy. It is the second oral targeted therapy to be approved in the US for this indication; the oral kinase inhibitor zongertinib (Hernexeos) was approved in August 2025.
Fields of Study & Subjects
Lung Cancer Treatments and Mutations
HER2/EGFR in Cancer Research
Lung Cancer Research Studies
Publication details
- Journal / source
- The medical letter on drugs and therapeutics/The medical letter
- Volume
- 68
- Issue
- 1748
- Pages
- e34–e35
- Publication date
- 6 February 2026
- Language
- EN